"Filgrastim" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
- G-CSF Recombinant, Human Methionyl
- G CSF Recombinant, Human Methionyl
- Recombinant-Methionyl Human Granulocyte Colony-Stimulating Factor
- Recombinant Methionyl Human Granulocyte Colony Stimulating Factor
- R metHuG CSF
- Filgrastim Sandoz
- Filgrastim Sndz
Below are MeSH descriptors whose meaning is more general than "Filgrastim".
Below are MeSH descriptors whose meaning is more specific than "Filgrastim".
This graph shows the total number of publications written about "Filgrastim" by people in this website by year, and whether "Filgrastim" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Filgrastim" by people in Profiles.
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 11 20; 38(33):3841-3850.
a-Tocopherol succinate- and AMD3100-mobilized progenitors mitigate radiation-induced gastrointestinal injury in mice. Exp Hematol. 2012 May; 40(5):407-17.
Drug-induced thrombocytopenia: an updated systematic review, 2010. Drug Saf. 2011 May 01; 34(5):437-8.
Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia. Biosci Trends. 2010 Oct; 4(5):273-8.
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Sep; 118(3):303-7.